Skip to main content
. 2019 Aug 27;9(9):70. doi: 10.1038/s41408-019-0228-2

Fig. 1. Proteasome activity in PBMC.

Fig. 1

a Maximum change from baseline in proteasome activity on days 8 or 15 (β2/2i, β1/1i, 5/5i proteasome subunits and global proteasome activity), mean of all patients. b Comparison of β2/2i/β1/1i, 5/5i ratio versus clinical response. c Active site labeling days 0 (baseline), 8, and 15 (n = 2 patients) and its densitometric evaluation of the bands